Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Biological Causes of Schizophrenia

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Psychological and Sociocultural Causes of Schizophrenia

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long range frontal/posterior phase synchronization during remembered pursuit task is impaired in schizophrenia.

Schizophrenia research·2014

Same author

Family history of psychosis moderates early auditory cortical response abnormalities in non-psychotic bipolar disorder.

Bipolar disorders·2013

Same author

Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders?

Journal of psychiatric research·2013

Same author

Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).

The American journal of psychiatry·2013

Same author

Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction.

Schizophrenia bulletin·2013

Same author

Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives.

The American journal of psychiatry·2013

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

Schizophrenia endophenotypes as treatment targets.

Gunvant K Thaker¹

¹University of Maryland School of Medicine, Maryland Psychiatric Research Center, Department of Psychiatry, PO Box 21247, Baltimore, MD 21228, USA. gthaker@mprc.umaryland.edu

Expert Opinion on Therapeutic Targets

|September 12, 2007

Summary

Schizophrenia treatments are limited, primarily addressing positive symptoms. Identifying stable, heritable brain deficits called endophenotypes offers novel molecular targets for developing more effective drugs for all symptom clusters.

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Published on: November 19, 2020

Related Experiment Videos

Last Updated: Jul 11, 2026

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Published on: November 19, 2020

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Schizophrenia is a complex disorder with diverse symptoms and functional impairments.
Current treatments primarily target positive symptoms, with limited efficacy for negative symptoms and functional deficits.
The historical focus on D2 dopamine receptors has yielded insufficient therapeutic advancements.

Purpose of the Study:

To highlight the need for novel drug discovery mechanisms in schizophrenia.
To introduce endophenotypes as stable, heritable neurobiological deficits.
To propose endophenotypes as a strategy for developing targeted schizophrenia therapeutics.

Main Methods:

Review of neurophysiological studies in schizophrenia over three decades.
Utilizing valid animal models to identify stable, etiological brain deficits (endophenotypes).
Analysis of genetic associations with identified endophenotypes.

Main Results:

Endophenotypes represent well-characterized neurobiological deficits with potential molecular targets.
Endophenotypes can reduce patient heterogeneity, enabling more precise subgroup identification.
Gene identification associated with endophenotypes is advancing drug development possibilities.

Conclusions:

Endophenotypes offer a promising avenue for developing novel drugs targeting specific schizophrenia symptom clusters and functional impairments.
Endophenotype-based drug development can enhance clinical trial statistical power.
Early identification of endophenotypes suggests potential for preventive strategies in schizophrenia.